Title of Activity:

Following a Path Toward Progress in GBM Treatment: Making Every Day Count


Release Date:

December 18, 2013



Expiration Date:

December 18, 2014


Estimated Time to Complete Activity:

1.75 Hours


Jointly sponsored by Postgraduate Institute for Medicine and CME Incite


This activity is supported by an educational grant from Genentech.



For questions regarding accreditation, please contact Postgraduate Institute for Medicine.

Intended Audience

This continuing medical education (CME)-certified activity has been developed for medical oncologists and healthcare professionals who manage patients with glioblastoma multiforme (GBM).



Statement of Need/Program Overview

Oncologists can lack the confidence to interpret and apply efficacy and safety data of bevacizumab treatment in patients with GBM. Clinicians can benefit from guidance about how to assess the benefit versus risk of treatment, while considering patient and caregiver goals and desires. Oncologists often find it difficult to stay abreast of emerging clinical trial data and the implications of trial results on clinical practice.

This engaging patient/physician documentary will focus on the stories of 3 patients with GBM. Our unique Virtual Rounds™ program aims to provide the learner with information needed to make informed treatment decisions, as well as clinical pearls and best practices regarding patient communication and insight into management strategies.



Educational Objectives

After completing this activity, the participant should be better able to:

  • Analyze the safety and efficacy of targeted agents in recurrent GBM and the implications of these results in clinical practice
  • Address patient and caregiver apprehension through effective communication regarding risk and benefit of treatment options, trends, quality-of-life concerns, and patient prognosis for recurrent GBM
  • Describe ongoing clinical trials of treatment for newly diagnosed GBM and how these results may guide clinicians toward better patient care


Faculty

David Reardon, MD
Clinical Director
Center for Neuro-Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Charles Raison, MD
Associate Professor of Psychiatry
Family & Consumer Sciences
University of Arizona
Tucson, Arizona


Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and CME Incite. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.



Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity



Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest or a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


David Reardon, MD

Consulting Fees: EMD Serono
Fees for non-CME/CE services: Genentech/Roche, Novartis, Merck/Schering.

Charles Raison, MD

Consulting Fees: Eli Lilly, Pamlab
Fees for non-CME/CE services: Pamlab

The patients included in this activity have nothing to disclose.

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following CME Incite planners and managers, Priya Wanchoo, MBBS, CCMEP and Rose Deeter O’Connor, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation and Request for Credit There are no fees for participating and receiving CME credit for this activity. During the period [release month, day] [year] through [expiration date], [year], participants must read the learning objectives and faculty disclosures and study the educational activity.



Media

Internet



Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.



Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



Posttest, Evaluation, and Attestation

To receive the certificate for CME, you must complete the posttest with a 70% or better score. Questions related to this activity are presented with multichoice answers. Select your answer from the list and continue to the next question until the posttest is finished. Upon completion of the posttest, you will be asked to fill out a form to evaluate this CME activity. Select your responses from the available options. Once the form is completed, you will be directed to the Attestation page where you will be asked to input the amount of time taken to complete this activity. Your certificate will be awarded after the Attestation page is submitted.



Hardware and Software Requirements

Broadband Connection to Internet, and a Webkit compatible browser such as Chrome, Safari, Firefox, IE9 with Cookies enabled and Pop-Ups allowed for the best experience.